Septerna Appoints Rajiv Patni, M.D., As Chief Medical Officer
AI summary by ChartPulse ยท Source: Nasdaq
Summary
Septerna Inc. has appointed Dr. Rajiv Patni as its new Chief Medical Officer, bringing over 20 years of experience in clinical development and regulatory affairs. His background includes senior positions at major pharmaceutical companies and oversight of numerous drug approvals, particularly in rare diseases and oncology. This strategic hire aims to enhance Septerna's leadership as it advances its pipeline of GPCR-targeted therapies into clinical trials. The company's stock closed at $40.52, reflecting a slight increase of 1.30%.
Key takeaways
- Dr. Rajiv Patni appointed as Chief Medical Officer of Septerna Inc.
- Brings extensive experience in clinical development and regulatory affairs from companies like Pfizer and Roche.
- Septerna's stock is currently trading around $40.52, with a yearly range of $11.70 to $51.10.
This is an AI-generated summary. Read the complete article at the original source:
Read full article at NasdaqChartPulse provides AI-generated summaries for educational purposes and links to the original sources. Nothing here is financial advice.